Literature DB >> 21150487

Adenosine A3 receptor agonist reduces early brain injury in subarachnoid haemorrhage.

Chunxia Luo1, Bin Yi, Guocai Tao, Mei Li, Zhi Chen, Weihua Tang, John H Zhang, Hua Feng.   

Abstract

Inflammation plays an important role in the pathogenesis of early brain injury after subarachnoid haemorrhage. Adenosine A3 receptor (A3R) activation produces anti-inflammatory effects. In this study, the effects of a selective A3R agonist, 2-chloro-N⁶-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (CL-IB-MECA), on early brain injury and inflammatory response after subarachnoid haemorrhage were studied. Our results showed that mortality, neurological impairment and brain oedema were significantly attenuated after the administration of CL-IB-MECA. Moreover, treatment with CL-IB-MECA inhibited microglial activation and reduced the expression of proinflammatory cytokines including tumour necrosis factor-α and interleukin-1β. These data suggest that activation of A3R provides a neuroprotective effect against brain injury after subarachnoid haemorrhage, and that these effects may be associated with the anti-inflammatory properties of A3R.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21150487     DOI: 10.1097/WNR.0b013e32833dbd13

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  7 in total

1.  Role of HCN channels in neuronal hyperexcitability after subarachnoid hemorrhage in rats.

Authors:  Bo Li; Chunxia Luo; Weihua Tang; Zhi Chen; Qiang Li; Bo Hu; Jiangkai Lin; Gang Zhu; John H Zhang; Hua Feng
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

2.  Enhanced neurodegeneration after a high dose of methamphetamine in adenosine A3 receptor null mutant mice.

Authors:  H Shen; Y Luo; S-J Yu; Y Wang
Journal:  Neuroscience       Date:  2011-08-10       Impact factor: 3.590

Review 3.  Investigational A₃ adenosine receptor targeting agents.

Authors:  Balázs Koscsó; Balázs Csóka; Pál Pacher; György Haskó
Journal:  Expert Opin Investig Drugs       Date:  2011-04-02       Impact factor: 6.206

Review 4.  Early brain injury, an evolving frontier in subarachnoid hemorrhage research.

Authors:  Mutsumi Fujii; Junhao Yan; William B Rolland; Yoshiteru Soejima; Basak Caner; John H Zhang
Journal:  Transl Stroke Res       Date:  2013-08       Impact factor: 6.829

5.  A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways.

Authors:  Kali Janes; Emanuela Esposito; Timothy Doyle; Salvatore Cuzzocrea; Dillip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  Pain       Date:  2014-09-19       Impact factor: 6.961

6.  A new drug design targeting the adenosinergic system for Huntington's disease.

Authors:  Nai-Kuei Huang; Jung-Hsin Lin; Jiun-Tsai Lin; Chia-I Lin; Eric Minwei Liu; Chun-Jung Lin; Wan-Ping Chen; Yuh-Chiang Shen; Hui-Mei Chen; Jhih-Bin Chen; Hsing-Lin Lai; Chieh-Wen Yang; Ming-Chang Chiang; Yu-Shuo Wu; Chen Chang; Jiang-Fan Chen; Jim-Min Fang; Yun-Lian Lin; Yijuang Chern
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

7.  Activation of adenosine A3 receptor reduces early brain injury by alleviating neuroinflammation after subarachnoid hemorrhage in elderly rats.

Authors:  Peng Li; Xiaojun Li; Peng Deng; Dandan Wang; Xuehong Bai; Yujie Li; Chunxia Luo; Karine Belguise; Xiaobo Wang; Xinchuan Wei; Zhengyuan Xia; Bin Yi
Journal:  Aging (Albany NY)       Date:  2020-11-30       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.